HONG KONG, China I March 16, 2025 I Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody ...
Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...
China's ophthalmic laser market is projected to grow at a CAGR of about 4% through 2033, driven by advancements in laser ...
Sino-American biopharma Ascentage Pharma has announced that olverembatinib has been granted Breakthrough Therapy Designation ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
Cumberland Pharmaceuticals' antibiotic Vibativ (telavancin) injection has gained approval from China’s National Medical Products Administration (NMPA), offering a new treatment option for ...
announces that China's National Medical Products Administration (NMPA) has approved SYCUME® (teprotumumab N01, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody ...
("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback